A report from Silicon Valley Bank breaking down 2021 investment trends reveals half-year figures already close to matching those for the whole of 2020 – itself a record-breaking year. In Vivo spoke with SVB’s EMEA head of life sciences and health care for a deeper dive into underlying causes.
With the pandemic putting a spotlight on the life sciences industry like never before, a surge in investment was to be expected; but the rate of growth has taken many by surprise.
The first half of 2021 saw investment in the sector jump to $47bn, more than double the same period last...
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
